Press Room

January 09, 2015

Biotheranostics Appoints Key Executives to Leadership Team

FOR IMMEDIATE RELEASE…Jan. 9, 2015…SAN DIEGO… Biotheranostics, Inc., a leader in molecular diagnostics for cancer, today announced the addition of two industry veterans to its senior management team as the company focuses on further commercial expansion of its Breast Cancer IndexSM (BCI) molecular test. Jennifer Skeen, Ph.D., joins Biotheranostics as Vice President of Clinical Operations, and Sue Beruti, M.D., joins as Medical Director. Nicolas Barthelemy, president and CEO of Biotheranostics, said, “It is very exciting for us to be able to attract leaders of Jen’s and Sue’s caliber. The combination of their significant experience in diagnostics and oncology, and their efforts in successfully launching lab developed tests and companion diagnostics adds to the quality of leadership talent we are assembling on our senior management team and equips us as we gear up for a period of exponential growth. We look forward to this important next stage in the evolution of Biotheranostics.” Skeen brings 10 years of clinical laboratory operations management experience to Biotheranostics, including positions at Pathway Genomics, Asuragen, and Alverno Clinical Laboratories. She has served in development, operational performance, quality assurance, and scientific leadership capacities, successfully launching oncology diagnostics and leading teams in strategic development and commercialization. At Asuragen, Skeen led the Genomic Services and CLIA laboratories in developing companion diagnostic tests and commercializing proprietary test offerings for oncology and genetic disorders, ensuring premier quality and compliance with national and state accreditation requirements. She holds a doctorate in molecular genetics and biochemistry from the University of Illinois, Chicago, and a bachelor’s degree in biology from the University of Illinois, Urbana-Champaign. Beruti has more than seven years of industry experience, with a strong focus in diagnostic and therapeutic oncology, pathology, biopharma, and companion diagnostics. She most recently was director of pathology and medical affairs at Genoptix (a Novartis Oncology company), where she led the Biopharma Medical Division and medical affairs group, which include providing oversight of multiple clinical trials in collaboration with major academic institutions and cancer centers. Beruti also is board certified in anatomic pathology, clinical pathology, and hematopathology. She received a bachelor’s degree in cell and molecular biology from the University of Michigan, and a medical degree and master’s degree in health administration from the Ohio State University College of Medicine and Public Health.

About Biotheranostics

Biotheranostics, Inc., is a leader in helping physicians improve the care and management of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its bioT3 Metastatic Cancer Solution combines accurate diagnosis with comprehensive biomarker information that allows improved treatment for metastatic cancer patients. Biotheranostics, a bioMérieux company, is based in San Diego. For more information, visit www.biotheranostics.com or www.AnswersBeyond5.com. Follow us on Twitter @answersbyond5.